Compare Moderna, Inc. (MRNA) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Moderna, Inc. trades at $137.39 (market cap $56.02B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.72. The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | PDBC | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | — |
52-Week High | $174.38 | $19.60 |
52-Week Low | $22.36 | $13.16 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.30, up 1.53% with a bullish technical signal from moving averages. Recent institutional buying from Concurrent Investment Advisors and Geneos Wealth Management signals confidence, though oscillators show bearish momentum with RSI levels indicating potential overbought conditions. The fund has delivered strong returns, outperforming the S&P 500 by nearly 10 percentage points since March 2024.
Commodity momentum faces headwinds despite geopolitical tensions, with a Seeking Alpha downgrade to hold citing weakening technicals. The fund offers defensive exposure amid market shifts away from tech, but investors face risks from potential commodity price volatility and Middle East conflict impacts on oil markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
